IL2 and neoplasm: After infusion, IL-2 promotes TIL survival via signal transducer and activator of transcription-5 (STAT5) signaling, while chemokine receptors like C-X-C chemokine receptor 3 (CXCR3) and C-C chemokine receptor 5 (CCR5) guide TIL migration to tumor sites (33).